Thrive Earlier Detection has drawn a substantial $257 million in its second venture capital round to help push its multi-cancer blood test through clinical trials toward FDA approval. The company ...
Thrive Earlier Detection has a clear, straightforward vision: help find cancers as early as possible, when they are most likely to be cured, by using a simple blood test. To prove it can work, the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results